Search Results
Your search for ,foR matches 32446 pages
Showing 12001 - 12050Potential Protective Effect of Ibrutinib Against Pulmonary Injury in Patients With COVID-19
In a letter published in the journal Blood, Steven P. Treon, MD, PhD, and colleagues reported a potential protective effect against pulmonary injury with the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib in patients diagnosed with COVID-19 who were receiving the agent for Waldenström’s...
Cognitive Impairment With Adjuvant Chemoendocrine vs Endocrine Therapy for Early Breast Cancer in the TAILORx Trial
In a study reported in the Journal of Clinical Oncology, Wagner et al found that patient-reported cognitive impairment was worse at 3 and 6 months in women with early breast cancer receiving adjuvant chemoendocrine therapy vs endocrine therapy alone in the TAILORx trial, with no significant...
FDA Approves Ibrutinib/Rituximab for CLL/SLL
On April 21, the U.S. Food and Drug Administration (FDA) expanded the indication of ibrutinib (Imbruvica) to include its combination with rituximab for the initial treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This review was conducted...
Hope S. Rugo, MD, on Talazoparib for Advanced Solid Tumors: Reduced Hospitalization and Supportive Care
Hope S. Rugo, MD, of the University of California, San Francisco, discusses an integrated analysis of five clinical trials, in phases I through III, for a variety of advanced cancers. Findings show that patients treated with talazoparib monotherapy had lower hospitalization rates (compared to those ...
Sara A. Hurvitz, MD, on Talazoparib vs Chemotherapy for Breast Cancer: Results From the EMBRACA Trial
Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses racial differences in self-reported outcomes of patients with HER2-negative, locally advanced or metastatic breast cancer and a germline BRCA1/2 mutation who received talazoparib vs physician’s choice of chemotherapy...
April Is the Cruelest Month
April is the cruelest month, breeding Lilacs out of the dead land, mixing Memory and desire, stirring Dull roots with spring rain. Winter kept us warm, covering Earth in forgetful snow, feeding A little life with dried tubers. —T.S. Eliot, The Burial of the Dead, The Waste Land, 1922 I started...
FDA Authorizes First COVID-19 Test for Patient At-Home Sample Collection
The U.S. Food and Drug Administration (FDA) authorized the first diagnostic test with a home collection option for COVID-19. Specifically, the FDA re-issued the emergency use authorization (EUA) for the Laboratory Corporation of America (LabCorp) COVID-19 RT-PCR Test to permit testing of samples...
Patients May Experience Increased Infections Preceding a Cancer Diagnosis
Patients may experience a greater occurrence of infections in the years preceding a cancer diagnosis, according to results from a study published by Inaida et al in Cancer Immunology Research. “Cancer can develop in an inflammatory environment caused by infections, immunity disruption, exposure to...
Survey Shows COVID-19 Pandemic Is Affecting Patients’ Access to Cancer Care
Patients with cancer and those who have recently completed treatment are finding it challenging to get necessary health care in the midst of the COVID-19 pandemic, and many are experiencing financial stress trying to afford care in an increasingly difficult economic environment. Delays in Care...
Addition of Capecitabine to Taxane/Anthracycline Adjuvant Chemotherapy for Triple-Negative Breast Cancer
In a Chinese phase III trial reported in the Journal of Clinical Oncology, Li et al found that the addition of capecitabine to taxane/anthracycline adjuvant therapy for triple-negative breast cancer was associated with improved disease-free survival. Study Details In the open-label multicenter...
'Switch Maintenance' Pembrolizumab for Metastatic Urothelial Cancer
In a phase II study reported in the Journal of Clinical Oncology, Matthew D. Galsky, MD, and colleagues found that maintenance pembrolizumab produced additional responses and improved progression-free survival vs placebo in patients with metastatic urothelial cancer who had at least stable disease...
Celebrating the Role of Nurses in Meeting the Current Challenges of Cancer Care Delivery
The coronavirus pandemic is being compared to a battlefield, with health-care workers seen as the front-line soldiers in the war against the disease. There is certainly truth to that, insofar as doctors and nurses in many countries now face an unprecedented workload in saving lives, along with the...
Quantitative Microelastography for Tumor Detection in Breast-Conserving Surgical Margins
A high-resolution, three-dimensional imaging technique, when combined with quantitative measurement of tissue elasticity, could accurately detect cancer within the resected margins of surgical specimens taken from patients undergoing breast-conserving surgery, according to a study published by...
PSA Dynamics and Response to Androgen-Deprivation Therapy
Adaptive treatments based on evolutionary principles may be an effective approach to prostate cancer treatment by preventing the development of drug resistance and prolonging patient survival. In an article in Nature Communications, Brady-Nicholls et al provided a closer look at a model and data...
FDA Approves Pemigatinib for Patients With Cholangiocarcinoma and an FGFR2 Rearrangement or Fusion
On April 17, the U.S. Food and Drug Administration (FDA) granted accelerated approval to pemigatinib (Pemazyre) for the treatment of adult patients with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or...
A Segregated-Team Workflow Model During the COVID-19 Pandemic in a Cancer Center
In an article published in Annals of Oncology, members of the National University Cancer Institute of Singapore (NCIS) workflow team described a segregated-team workflow model that allowed continuation of cancer care at the comprehensive cancer center during the COVID-19 outbreak in Singapore....
Recurrence of Immune-Related Adverse Events After Checkpoint Inhibitor Rechallenge in Patients With Cancer
A study reported in JAMA Oncology by Dolladille et al using pharmacovigilance data from the World Health Organization database VigiBase found that the same immune-related adverse events (irAEs) associated with discontinuation of immune checkpoint inhibitor therapy recurred in 28.8% of patients...
FDA Approves Tucatinib in Combination With Trastuzumab/Capecitabine for Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
On April 17, the U.S. Food and Drug Administration (FDA) granted approval to tucatinib (Tukysa) in combination with trastuzumab/capecitabine for adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received one or...
FDA Encourages Plasma Donation From Patients Who Have Recovered From COVID-19, Collaborates to Produce Supplies for Testing
This week, the U.S. Food and Drug Administration (FDA) issued a statement encouraging patients who have fully recovered from COVID-19 for at least 2 weeks to donate plasma, in order to ramp up supply of convalescent plasma for treatment of infected individuals. The agency also announced that spun...
Program for Improving VTE Risk Assessment, Patient Education, and Prophylaxis Use in an Ambulatory Cancer Clinic
In a study reported in JCO Oncology Practice, Holmes et al found that a program instituted at the University of Vermont Medical Center was successful in improving venous thromboembolism (VTE) risk assessment, patient education, and rates of prophylaxis use in patients initiating anticancer...
Hospitals Report Challenges in Responding to the COVID-19 Pandemic
In a report released by the U.S. Department of Health and Human Services (HHS), hospitals reported the most significant challenges they are facing during the COVID-19 pandemic. Survey Methods Brief telephone interviews were conducted from March 23 to March 27, 2020, with one or more administrators ...
Pooled Meta-Analysis of Cancer Prevalence in Patients With COVID-19 Infection
In a meta-analysis reported in JCO Global Oncology, Desai et al found a pooled prevalence of cancer of 2.0% among patients with COVID-19 infection. Key Findings A literature search identified 11 reports providing data on prevalence of cancer in patients with COVID-19 infection. The overall...
Addition of Pembrolizumab to Docetaxel for Previously Treated Immunotherapy-Naive Patients With Advanced NSCLC
In the single-institution phase II PROLUNG trial reported in JAMA Oncology, Arrieta et al found that the addition of pembrolizumab to docetaxel improved objective response rate and progression-free survival in immunotherapy-naive patients with advanced non–small cell lung cancer (NSCLC) who...
Multidisciplinary Recommendations for Breast Cancer Care During the COVID-19 Pandemic
The American Society of Breast Surgeons (ASBrS), the National Accreditation Program for Breast Centers (NAPBC), the National Comprehensive Cancer Network® (NCCN®), the Commission on Cancer (CoC) of the American College of Surgeons, and the American College of Radiology (ACR) have released new joint ...
Aspirin Use and Risk of Cancers of the Digestive Tract
Aspirin may be associated with a reduction in the risk of developing several cancers of the digestive tract. The largest and most comprehensive analysis to date of the link between aspirin and digestive tract cancers, published by Bosetti et al in Annals of Oncology, found reductions in the risk of ...
Practical Approach to Management of Patients With Cancer During the COVID-19 Pandemic: An International Collaborative Group Statement
In an article published in The Oncologist, an international collaborative group outlined issues and potential management approaches for the treatment of patients with cancer during the COVID-19 pandemic. Key issues facing cancer treatment and some of the potential measures for addressing these...
Patterns in Physician Use of Extended-Fraction Radiation Therapy for Bone Metastases
Routine use of extended-fraction radiation therapy—defined as more than 10 fractions—for the palliative treatment of bone metastases is considered a low-value intervention by the American Society for Radiation Oncology. In a retrospective cohort study reported in JCO Oncology Practice, Gupta et al...
Durvalumab for Solid Tumors in Patients With Virologically Controlled HIV-1 Infection
In the Spanish phase II DURVAST trial reported in JAMA Oncology, Gonzalez-Cao et al found that treatment with durvalumab was feasible, safe, and active in patients with solid tumors and virologically controlled HIV-1 infection. As stated by the investigators, “Concerns about the safety and...
Mind-Body Therapies for Relieving Anxiety and Stress in Patients With Cancer During COVID-19 Pandemic
The rapid spread of the novel coronavirus disease (COVID-19) has dramatically disrupted societal life within a very short time. Patients with cancer in particular can be affected by delays in routine medical care in addition to experiencing heightened anxiety and stress associated with the threat...
FDA Approves Mitomycin Gel for Low-Grade Upper Tract Urothelial Cancer
On April 15, the U.S. Food and Drug Administration (FDA) approved mitomycin (Jelmyto) for adult patients with low-grade upper tract urothelial cancer. OLYMPUS Trial Efficacy determination was based on OLYMPUS, an ongoing, single-arm, multicenter trial enrolling 71 patients with treatment-naive or...
Online Mind-Body Resources for Oncologists and Health-Care Workers During the COVID-19 Pandemic
The spread of COVID-19 continues to have a dramatic impact around the world, disrupting social lives and the delivery of oncologic treatments to patients with cancer. Even under “normal” circumstances, health-care professionals, including those in oncology, are prone to occupational stress....
First-Line Durvalumab With or Without Tremelimumab vs Chemotherapy for Metastatic NSCLC: MYSTIC Study
As reported in JAMA Oncology by Naiyer A. Rizvi, MD, and colleagues, the phase III MYSTIC trial showed no overall survival benefit with durvalumab vs chemotherapy, or overall or progression-free survival benefit with durvalumab/tremelimumab vs chemotherapy, as first-line treatment in patients with...
Outcomes in Patients With Retroperitoneal Soft-Tissue Sarcoma by Hospital Type
In a study reported in JCO Oncology Practice, Villano et al found that increased hospital surgical volume was associated with overall improved survival in patients undergoing surgery for retroperitoneal soft-tissue sarcoma. However, increased volume was associated with poorer survival in patients...
Joint Publication Focuses on Clinical Practice Guidelines on Opioid Use for Pain Management
A recently published article by Schatz et al offers new clarity around the use of prescription opioids in pain management for people with a diagnosis or history of cancer and chronic pain. The joint publication, which appeared in both JNCCN—Journal of the National Comprehensive Cancer Network and...
Immune Checkpoint Inhibitor Treatment for Patients With Cancer During the COVID-19 Pandemic
In an article published in the journal Immunotherapy, Melissa Bersanelli, MD, of the Medical Oncology Unit, University Hospital of Parma, Italy, discusses controversies regarding the use of immune checkpoint inhibitor therapy in patients with cancer during the COVID-19 pandemic, suggesting that...
Delayed Targeted Intraoperative Radiotherapy vs Whole-Breast Radiotherapy in Early Breast Cancer
As reported in JAMA Oncology by Jayant S. Vaidya, MBBS, PhD, and colleagues, the phase III TARGIT-A trial showed that delayed second-procedure targeted intraoperative radiotherapy (TARGIT-IORT) was not noninferior to whole-breast external-beam radiotherapy (EBRT) in preventing local recurrence of...
Karen Wonders, PhD, on Benefits of Exercise During Cancer Treatment
Karen Wonders, PhD, of Wright State University, discusses the safety and efficacy of exercise during cancer treatment in minimizing toxicities and addressing the short- and long-term effects of cancer therapy. Dr. Wonders suggests that exercise becomes a standard of care for patients with cancer...
Differences in Melanoma Incidence in Men vs Women by Age and Anatomic Site
In a study published by Olsen et al in JAMA Dermatology, researchers found that in predominantly fair-skinned populations, melanoma incidence differed by age and anatomic site in men and women. Methods A cross-sectional analysis of sex- and site-specific trends was performed for white patients...
Neoadjuvant Immunotherapy in Early-Stage Colon Cancer
Patients with localized colon cancer may benefit from a short course of neoadjuvant immunotherapy, according to findings from the exploratory phase II NICHE study published by Myriam Chalabi, MD, and colleagues in Nature Medicine. Study Results Forty patients with two colon cancer subtypes—either ...
ASCO Releases New Guidance on Allocation of Limited Resources in the Oncology Community During COVID-19 Pandemic
ASCO has released a set of recommendations to support the oncology community as health-care institutions across the United States face potentially difficult decisions around the allocation of scarce health-care resources during the COVID-19 pandemic. In some geographic areas, the ongoing crisis is...
Postdiagnosis Weight and Mortality in Survivors of Nonmetastatic Prostate Cancer
In a study reported in the Journal of Clinical Oncology, Troeschel et al found that postdiagnosis obesity was associated with higher cardiovascular disease mortality and all-cause mortality, and postdiagnosis weight gain was associated with higher all-cause and prostate cancer–specific mortality in ...
Activity of Pembrolizumab in Patients With NSCLC Brain Metastases
As reported in The Lancet Oncology by Sarah B. Goldberg, MD, MPH, and colleagues, continued follow-up of the non–small cell lung cancer (NSCLC) cohort of a single-institution phase II trial showed that pembrolizumab produced responses in patients with brain metastases and programmed cell death...
Report on the ASH COVID-19 Registry for Malignant Hematology
We begin with an interview with William A. Wood, MD, MPH, of the University of North Carolina, Chapel Hill. Dr. Wood is current Chair of the ASH Research Collaborative’s Data Hub Oversight Group, and he spoke with us about the new COVID-19 Registry for Malignant Hematology. Next, we’ll move onto a...
William J. Gradishar, MD, on Innovating Pathways for Patient Self-Management in Breast Cancer
William J. Gradishar, MD, of Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the “4R Model” (Right Information, Care, Patient, and Time) which has proved to be a promising method for patient self-management. Patient care sequence plans markedly improved several...
FDA Pipeline: Priority Reviews for Immunotherapy Based on Biomarker Status, Combination First-Line Therapy in Lung Cancer
Over the past week, the U.S. Food and Drug Administration (FDA) granted Priority Review to an immunotherapeutic agent for solid tumors with a high tumor mutational burden and to a combination treatment for the first-line treatment of metastatic or recurrent non–small cell lung cancer. The agency...
ASCO’s New COVID-19 Cancer Registry Aims to Understand Impact on Patients During Pandemic, Inform Future Care
On April 10, ASCO launched the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient...
NCCN Issues Guidance on Improving COVID-19 Safety for Patients and Health-Care Providers
The National Comprehensive Cancer Network’s® (NCCN®) Best Practices Committee has published a preprint article in JNCCN—Journal of the National Comprehensive Cancer Network detailing their recommendations for keeping patients with cancer, as well as their caregivers and health-care staff, as safe...
‘Textbook Outcome’ in Patients Undergoing Resection of Pancreatic Neuroendocrine Tumors
In a study reported in the Journal of Surgical Oncology, Timothy M. Pawlik, MD, MPH, PhD, and colleagues found that approximately half of patients undergoing resection of pancreatic neuroendocrine tumors (PNETs) had a “textbook outcome”—a result associated with significantly improved disease-free...
Outcomes of COVID-19 Infection in Patients With Cancer in Wuhan, China
In a retrospective cohort study reported in the Annals of Oncology, Li Zhang, MD, of the Department of Oncology, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China, and colleagues described characteristics and outcomes of COVID-19 infection in 28 patients with cancer from...
FDA Approves Selumetinib for Pediatric Patients With NF1 and Symptomatic Inoperable Plexiform Neurofibromas
On April 10, the U.S. Food and Drug Administration (FDA) approved selumetinib (Koselugo) for pediatric patients aged 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic inoperable plexiform neurofibromas. Selumetinib, a kinase inhibitor, is the first therapy approved for...
